What should I avoid while taking Carvedilol 3.125mg tablets?

Take with food. Food slows the absorption and reduces the incidence of adverse effects. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Carvedilol 3.125mg tablets?

Carvedilol 3.125mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Carvedilol 3.125mg tablets?

Carvedilol 3.125mg tablets is the generic name. It is available under brand names including: Carvedilol 3.125mg tablets, Carvedilol 3.125mg tablets, Carvedilol 3.125mg tablets, Carvedilol 3.125mg tablets, Carvedilol 3.125mg tablets and 25 more. (Source: NHS dm+d — Actual Medicinal Products)

Carvedilol 3.125mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

3.125mg

Oral

Licensed beta-blocker

Beta-adrenoceptor blocking drugs

Active ingredients:

Carvedilol

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 02.04

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC C07AG02

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Primary care groupBrowse groups

NHS medication clusters used to compare prescribing patterns across GP practices

Licensed beta-blocker

Check interactions for Carvedilol

1 safety notice

Pharmacogenomics

Genetic variations that may affect drug response

1 known genetic variation may influence how your body responds to Carvedilol 3.125mg tablets.Gene involved: ADRB1

These are known genetic variations. They don't mean the medicine won't work for you — speak to your doctor or a pharmacogenomics specialist for personalised advice. Source: DrugBank (CC BY-NC 4.0).

rs1801253

ADRB1

Beta-1 adrenergic receptor

Patients with this genotype in ADRB1 have an increased likelihood of responding to carvedilol for the treatment of increased blood pressure.

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Carvedilol

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Carvedilol

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Carvedilol

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

30 branded products available

30 productsShow details

30 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Carvedilol on the MHRA register

Carvedilol 3.125mg tablets

Teva UK Ltd

Carvedilol 3.125mg tablets

Alliance Healthcare (Distribution) Ltd

Carvedilol 3.125mg tablets

A A H Pharmaceuticals Ltd

Carvedilol 3.125mg tablets

Almus Pharmaceuticals Ltd

Carvedilol 3.125mg tablets

Sigma Pharmaceuticals Plc

Carvedilol 3.125mg tablets

Phoenix Healthcare Distribution Ltd

Carvedilol 3.125mg tablets

Bristol Laboratories Ltd

Carvedilol 3.125mg tablets

Milpharm Ltd

Carvedilol 3.125mg tablets

Ennogen Healthcare International Ltd

Carvedilol 3.125mg tablets

Medihealth (Northern) Ltd

Carvedilol 3.125mg tablets

Relonchem Ltd

Eucardic 3.125mg tablets

Roche Products Ltd

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Price & daily doseShow details

£0.72indicative price

This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.

View full Drug Tariff

Source: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.

WHO defined daily dose (DDD)

37.5 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Labetalol 50mg/10ml solution for injection ampoules

Injection

50mg/10ml

Same therapeutic group

Labetalol 5mg/5ml oral solution

Oral solution

5mg/5ml

Same therapeutic group

Labetalol 5mg/5ml oral suspension

Oral suspension

5mg/5ml

Same therapeutic group

Carvedilol 1.5mg/5ml oral suspension

Oral suspension

1.5mg/5ml

Same therapeutic group

Labetalol 1.5mg/5ml oral suspension

Oral suspension

1.5mg/5ml

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Carvedilol

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(1)

Cirrhosis in over 16s: assessment and management (NG50)

NG50

NICE guideline

Updated Sept 2023

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Carvedilol

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42372711000001106

dm+d ID

42372711000001106

VTM (Virtual Therapeutic Moiety)

775077004

VMP (Virtual Medicinal Product)

42372711000001106

BNF code

02040000

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

C07AG02

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

34 found

Half-life

7-10 hours

Mechanism

Carvedilol inhibits exercise induced tachycardia through its inhibition of beta adrenoceptors.

Food interactions

1 warning

Human targets

18 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

25-35%

Carvedilol has a bioavailability of 25-35%.
[A182306][L7889][L7892]

Carvedilol has a T_max of 1 to 2 hours.
[A182306]…

Half-life

7-10 hours

The half life of carvedilol is between 7-10 hours, though significantly shorter half lives have also been reported.
[A182306][L7889][L7892]

Protein binding

98%

Carvedilol is 98% protein bound in plasma.
[L7889][L7892]
95% of carvedilol is bound to serum albumin.
[A182306]

Volume of distribution

1.5-2L/kg

Carvedilol has a volume of distribution of 1.5-2L/kg[A182306] or 115L.
[L7892]

Metabolism

Carvedilol can be hydroxlated at the 1 position by CYP2D6, CYP1A2, or CYP1A1 to form 1-hydroxypheylcarvedilol; at the 4 position by CYP2D6, CYP2E1,…

Elimination

16%

16% of carvedilol is excreted in the urine with <2% excreted as unmetabolized drug.
[A182306]
Carvedilol is primarily excreted in the bile and feces.
[L7889][L7892]

Clearance

0.52L/kg

The plasma clearance of carvedilol has been reported as 0.52L/kg[A182306] or 500-700mL/min.
[L7889][L7892]

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889][L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889][L7892] The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension.[A182306]

Carvedilol was granted FDA approval on 14 September 1995.[L7889]

Properties:

solid

Avg. mass: 406.47 Da

View FDA drug label

DrugBank indication

Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.
[L7889][L7892]

Also known as(191)

(+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol

Carvédilol

Carvedilol

Carvedilolum

ADRB1R

B1AR

Beta-1 adrenoceptor

Beta-1 adrenoreceptor

Dosage forms(50)

Tablet (Oral)

Tablet (Oral) — 25.000 mg

Tablet (Oral) — 1250000 mg

Tablet (Oral) — 2500000 mg

Tablet, film coated (Oral)

Tablet, film coated (Oral) — 12.5 MG

Tablet, film coated (Oral) — 25 MG

Tablet, film coated (Oral) — 6.25 MG

Molecular properties(19)

Drug interactions(1757)

Known interactions with other medications. Always consult a healthcare professional.

Duloxetine

Major

DB00476

The risk or severity of orthostatic hypotension and syncope can be increased when Carvedilol is combined with Duloxetine.

Check this interaction

Levodopa

Major

DB01235

The risk or severity of hypotension and orthostatic hypotension can be increased when Carvedilol is combined with Levodopa.

Check this interaction

Risperidone

Moderate

DB00734

Carvedilol may increase the hypotensive activities of Risperidone.

Check this interaction

Afatinib

Unknown severity

DB08916

The serum concentration of Afatinib can be increased when it is combined with Carvedilol.

Check this interaction

Bosutinib

Unknown severity

DB06616

The serum concentration of Bosutinib can be increased when it is combined with Carvedilol.

Check this interaction

Brentuximab vedotin

Unknown severity

DB08870

The serum concentration of Brentuximab vedotin can be increased when it is combined with Carvedilol.

Check this interaction

Cyclosporine

Unknown severity

DB00091

The serum concentration of Cyclosporine can be increased when it is combined with Carvedilol.

Check this interaction

Colchicine

Unknown severity

DB01394

The serum concentration of Colchicine can be increased when it is combined with Carvedilol.

Check this interaction

Edoxaban

Unknown severity

DB09075

The serum concentration of Edoxaban can be increased when it is combined with Carvedilol.

Check this interaction

Ledipasvir

Unknown severity

DB09027

The serum concentration of Ledipasvir can be increased when it is combined with Carvedilol.

Check this interaction

Naloxegol

Unknown severity

DB09049

The serum concentration of Naloxegol can be increased when it is combined with Carvedilol.

Check this interaction

Pazopanib

Unknown severity

DB06589

The serum concentration of Pazopanib can be increased when it is combined with Carvedilol.

Check this interaction

Prucalopride

Unknown severity

DB06480

The serum concentration of Prucalopride can be increased when it is combined with Carvedilol.

Check this interaction

Ranolazine

Unknown severity

DB00243

The serum concentration of Ranolazine can be increased when it is combined with Carvedilol.

Check this interaction

Silodosin

Unknown severity

DB06207

The excretion of Silodosin can be decreased when combined with Carvedilol.

Check this interaction

Topotecan

Unknown severity

DB01030

The serum concentration of Topotecan can be increased when it is combined with Carvedilol.

Check this interaction

Ceritinib

Moderate

DB09063

Carvedilol may increase the bradycardic activities of Ceritinib.

Check this interaction

Ruxolitinib

Moderate

DB08877

Ruxolitinib may increase the bradycardic activities of Carvedilol.

Check this interaction

Deferasirox

Unknown severity

DB01609

The serum concentration of Carvedilol can be increased when it is combined with Deferasirox.

Check this interaction

Peginterferon alfa-2b

Unknown severity

DB00022

The serum concentration of Carvedilol can be increased when it is combined with Peginterferon alfa-2b.

Check this interaction

Leflunomide

Unknown severity

DB01097

The serum concentration of Carvedilol can be decreased when it is combined with Leflunomide.

Check this interaction

Teriflunomide

Unknown severity

DB08880

The serum concentration of Carvedilol can be decreased when it is combined with Teriflunomide.

Check this interaction

Amifostine

Moderate

DB01143

Carvedilol may increase the hypotensive activities of Amifostine.

Check this interaction

Diazoxide

Moderate

DB01119

Diazoxide may increase the hypotensive activities of Carvedilol.

Check this interaction

Methylphenidate

Moderate

DB00422

Methylphenidate may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Dexmethylphenidate

Moderate

DB06701

Dexmethylphenidate may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Obinutuzumab

Moderate

DB08935

Carvedilol may increase the hypotensive activities of Obinutuzumab.

Check this interaction

Pentoxifylline

Moderate

DB00806

Pentoxifylline may increase the hypotensive activities of Carvedilol.

Check this interaction

Rituximab

Moderate

DB00073

Carvedilol may increase the hypotensive activities of Rituximab.

Check this interaction

Desmopressin

Moderate

DB00035

Desmopressin may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Doxapram

Moderate

DB00561

Doxapram may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Phenmetrazine

Moderate

DB00830

Phenmetrazine may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Naratriptan

Moderate

DB00952

Naratriptan may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Rizatriptan

Moderate

DB00953

Rizatriptan may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Dopamine

Moderate

DB00988

Dopamine may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Epicaptopril

Moderate

DB02032

Epicaptopril may decrease the antihypertensive activities of Carvedilol.

Check this interaction

1-benzylimidazole

Moderate

DB04581

1-benzylimidazole may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Amineptine

Moderate

DB04836

Amineptine may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Naluzotan

Moderate

DB05562

Naluzotan may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Nitrous oxide

Moderate

DB06690

Nitrous oxide may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Cinitapride

Moderate

DB08810

Cinitapride may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Tyramine

Moderate

DB08841

Tyramine may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Ifenprodil

Moderate

DB08954

Ifenprodil may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Dimetacrine

Moderate

DB08996

Dimetacrine may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Butriptyline

Moderate

DB09016

Butriptyline may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Moxisylyte

Moderate

DB09205

Moxisylyte may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Oxaprotiline

Moderate

DB09307

Oxaprotiline may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Atipamezole

Moderate

DB11481

Atipamezole may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Tetrahydrocannabivarin

Moderate

DB11755

Tetrahydrocannabivarin may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Piclozotan

Moderate

DB12361

Piclozotan may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Showing 50 of 1757 interactions

Food & lifestyle interactions

Take With Food

Take with food. Food slows the absorption and reduces the incidence of adverse effects.

Toxicity & overdose

Patients experiencing an overdose may present with hypotension, bradycardia, cardiac insufficiency, cardiogenic shock, and cardiac arrest.
[L7889][L7892]
Patients should remain in a supine position and may be given atropine for bradycardia and glucagon followed by sympathomimetics to support cardiovascular function.
[L7889][L7892]

How it works

Mechanism of action

Carvedilol inhibits exercise induced tachycardia through its inhibition of beta adrenoceptors.[A182306] Carvedilol's action on alpha-1 adrenergic receptors relaxes smooth muscle in vasculature, leading to reduced peripheral vascular resistance and an overall reduction in blood pressure.[A1929][A182306] At higher doses, calcium channel blocking and antioxidant activity can also be seen.[A1929] The antioxidant activity of carvedilol prevents oxidation of low density lipoprotein and its uptake into coronary circulation.[A1929]

Pharmacodynamics

Carvedilol reduces tachycardia through beta adrenergic antagonism and lowers blood pressure through alpha-1 adrenergic antagonism.[L7889][L7892] It has a long duration of action as it is generally taken once daily and has a broad therapeutic index as patients generally take 10-80mg daily.[L7889][L7892] Patients taking carvedilol should not abruptly stop taking this medication as this may exacerbate coronary artery disease.[L7889][L7892]

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Carvedilol has a bioavailability of 25-35%.
[A182306][L7889][L7892]

Carvedilol has a T_max of 1 to 2 hours.
[A182306]
Taking carvedilol with a meal increases T_max without increasing AUC.
[A182306]
Carvedilol doses of 50mg lead to a C_max of 122-262µg/L and an AUC of 717-1600µg/L\*h.
[A182306]
Carvedilol doses of 25mg lead to a C_max of 24-151µg/L and an AUC of 272-947µg/L\*h.
[A182306]
Carvedilol doses of 12.5mg lead to a C_max of 58-69µg/L and an AUC of 208-225µg/L\*h.
[A182306]

Half-life

The half life of carvedilol is between 7-10 hours, though significantly shorter half lives have also been reported.
[A182306][L7889][L7892]

Protein binding

Carvedilol is 98% protein bound in plasma.
[L7889][L7892]
95% of carvedilol is bound to serum albumin.
[A182306]

Volume of distribution

Carvedilol has a volume of distribution of 1.5-2L/kg[A182306] or 115L.
[L7892]

Metabolism

Carvedilol can be hydroxlated at the 1 position by CYP2D6, CYP1A2, or CYP1A1 to form 1-hydroxypheylcarvedilol; at the 4 position by CYP2D6, CYP2E1, CYP2C9, or CYP3A4 to form 4'-hydroxyphenylcarvedilol; at the 5 position by CYP2D6, CYP2C9, or CYP3A4 to form 5'-hydroxyphenylcarvedilol; and at the 8 position by CYP1A2, CYP3A4, and CYP1A1 to form 8-hydroxycarbazolylcarvedilol.
[A39000]
Carvedilol can also be demethylated by CYP2C9, CYP2D6, CYP1A2, or CYP2E1 to form O-desmethylcarvedilol.
[A39000]
Carvedilol and its metabolites may undergo further sulfate conjugation or glucuronidation before elimination.
[A39000]
Carvedilol can be O-glucuronidated by UGT1A1, UGT2B4, and UGT2B7 to form carvedilol glucuronide.
[A182303]

Route of elimination

16% of carvedilol is excreted in the urine with <2% excreted as unmetabolized drug.
[A182306]
Carvedilol is primarily excreted in the bile and feces.
[L7889][L7892]

Clearance

The plasma clearance of carvedilol has been reported as 0.52L/kg[A182306] or 500-700mL/min.
[L7889][L7892]

Drug targets(18)

Proteins and enzymes this drug interacts with in the body

Beta-1 adrenergic receptor

BE0000172

ADRB1

antagonist

Specific functionalpha-2A adrenergic receptor binding

Cellular location

Cell membrane

General function & pharmacology

Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.

Involved in the regulation of sleep/wake behaviors PMID:31473062

Beta-2 adrenergic receptor

BE0000694

ADRB2

antagonist

Specific functionadenylate cyclase binding

Cellular location

Cell membrane

General function & pharmacology

Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine

Alpha-1B adrenergic receptor

BE0000575

ADRA1B

antagonist

Specific functionalpha1-adrenergic receptor activity

Cellular location

Nucleus membrane

General function & pharmacology

This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes

Alpha-1A adrenergic receptor

BE0000501

ADRA1A

antagonist

Specific functionalpha1-adrenergic receptor activity

Cellular location

Nucleus membrane

General function & pharmacology

Alpha-1D adrenergic receptor

BE0000715

ADRA1D

antagonist

Specific functionalpha1-adrenergic receptor activity

Cellular location

Cell membrane

General function & pharmacology

This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium

Metabolizing enzymes(10)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP1A2Cytochrome P450 1A2

substrate

CYP3A4Cytochrome P450 3A4

substrate

CYP1A1Cytochrome P450 1A1

substrate

CYP2E1Cytochrome P450 2E1

substrate

UGT1A1UDP-glucuronosyltransferase 1A1

substrate

UGT2B4UDP-glucuronosyltransferase 2B4

substrate

UGT2B7UDP-glucuronosyltransferase 2B7

substrate

CYP2C9Cytochrome P450 2C9

substrate

CYP2D6Cytochrome P450 2D6

substrate

XDHXanthine dehydrogenase/oxidase

inhibitor

Transporters(1)

Proteins that transport this drug across cell membranes

ATP-dependent translocase ABCB1

BE0001032

ABCB1

inhibitor

Specific functionABC-type xenobiotic transporter activity

Cellular location

Cell membrane

General function & pharmacology

Translocates drugs and phospholipids across the membrane .
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548

Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218

Carriers(1)

Proteins that carry this drug through the body

Albumin

BE0000530

ALB

binder

Specific functionantioxidant activity

Cellular location

Secreted

General function & pharmacology

Binds water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs (Probable). Its main function is the regulation of the colloidal osmotic pressure of blood (Probable). Major zinc transporter in plasma, typically binds about 80% of all plasma zinc .
PMID:19021548
Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity).

Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner (By similarity). The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood (By similarity). The rank order of affinity is zinc > calcium > magnesium (By similarity).

Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli .
PMID:6234017
Does not prevent iron uptake by the bacterial siderophore aerobactin PMID:6234017

Biological pathways(1)

Carvedilol Action Pathway

Involved compounds

ATP,Calcium,Carvedilol,Magnesium cation,Potassium cation

Scientific references(4)

Vanderhoff B.T., Ruppel H.M., Amsterdam P.B.

β‐Blockers: Carvedilol Protects Better Against Vascular Events Than Metoprolol in Heart Failure.

Congestive Heart Failure

200713(3):183-184. doi: 10.1111/j.1527-5299.2007.623922.x

PMID: 9824960 DOI: 10.1111/j.1527-5299.2007.623922.x

Oldham H.G., Clarke S.E.

In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine.

Biopharmaceutics & Drug Disposition

201132(7):398-407. doi: 10.1002/bdd.768

PMID: 9280405 DOI: 10.1002/bdd.768

Takekuma Y., Yagisawa K., Sugawara M.

Mutual inhibition between carvedilol enantiomers during racemate glucuronidation mediated by human liver and intestinal microsomes.

Biological Pharmacy Bull

201235(2):151-63. doi: 10.1248/bpb.35.151

PMID: 22293344 DOI: 10.1248/bpb.35.151

Morgan T.

Clinical pharmacokinetics and pharmacodynamics of carvedilol.

Clinical Pharmacokinetics

1994 May26(5):335-46. doi: 10.2165/00003088-199426050-00002

PMID: 7914479 DOI: 10.2165/00003088-199426050-00002

ATC classification(2 codes)

ATC C07AG02

ATC C07FX06

Affected organisms(1)

Humans and other mammals

International brands(1)

Salt forms(1)

Carvedilol phosphate(DBSALT001201)

Experimental properties(3)

External resources(2)

RxList Drugs.com

Commercial products(677)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Carvedilol

DB01136

CAS number

72956-09-3

UNII (FDA)

0K47UL67F2

InChI Key (molecular fingerprint)

OGHNVEJMJSYVRP-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

1188

ChEBI

3441

PubChem Compound

2585

PubChem Substance

46505146

KEGG Compound

C06875

KEGG Drug

D00255

ChemSpider

2487

BindingDB

25759

PharmGKB

PA448817

Therapeutic Targets Database

DAP000135

IUPHAR

551

Guide to Pharmacology

551

Wikipedia

Carvedilol

ChEMBL

CHEMBL723

RxCUI

20352

HUGO Gene Nomenclature Committee (HGNC)

HGNC:285

GenAtlas

ADRB1

GeneCards

ADRB1

GenBank Gene Database

J03019

GenBank Protein Database

178200

IUPHAR

Guide to Pharmacology

UniProtKB

P08588

UniProt Accession

ADRB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:286

GenAtlas

ADRB2

GeneCards

ADRB2

GenBank Gene Database

Y00106

GenBank Protein Database

29371

IUPHAR

Guide to Pharmacology

UniProtKB

P07550

UniProt Accession

ADRB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:278

GenAtlas

ADRA1B

GeneCards

ADRA1B

GenBank Gene Database

M99589

IUPHAR

Guide to Pharmacology

UniProtKB

P35368

UniProt Accession

ADA1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:277

GenAtlas

ADRA1A

GeneCards

ADRA1A

GenBank Gene Database

D25235

GenBank Protein Database

433201

IUPHAR

Guide to Pharmacology

UniProtKB

P35348

UniProt Accession

ADA1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:280

GenAtlas

ADRA1D

GeneCards

ADRA1D

GenBank Gene Database

M76446

GenBank Protein Database

177807

IUPHAR

Guide to Pharmacology

UniProtKB

P25100

UniProt Accession

ADA1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:7706

GenAtlas

NDUFC2

GeneCards

NDUFC2

GenBank Gene Database

AF087659

GenBank Protein Database

4191346

UniProtKB

O95298

UniProt Accession

NDUC2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12680

GenAtlas

VEGF

GeneCards

VEGFA

GenBank Gene Database

M32977

GenBank Protein Database

181971

UniProtKB

P15692

UniProt Accession

VEGFA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:7940

GenAtlas

NPPB

GeneCards

NPPB

GenBank Gene Database

M31776

GenBank Protein Database

179515

UniProtKB

P16860

UniProt Accession

ANFB_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4274

GenAtlas

GJA1

GeneCards

GJA1

GenBank Gene Database

X52947

GenBank Protein Database

29917

UniProtKB

P17302

UniProt Accession

CXA1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6251

GenAtlas

KCNH2

GeneCards

KCNH2

GenBank Gene Database

U04270

GenBank Protein Database

487738

IUPHAR

572

Guide to Pharmacology

572

UniProtKB

Q12809

UniProt Accession

KCNH2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12663

GenAtlas

VCAM1

GeneCards

VCAM1

GenBank Gene Database

M30257

GenBank Protein Database

179886

UniProtKB

P19320

UniProt Accession

VCAM1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:283

GenAtlas

ADRA2C

GeneCards

ADRA2C

GenBank Gene Database

J03853

GenBank Protein Database

178194

IUPHAR

Guide to Pharmacology

UniProtKB

P18825

UniProt Accession

ADA2C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:282

GenAtlas

ADRA2B

GeneCards

ADRA2B

GenBank Gene Database

M34041

GenBank Protein Database

178198

IUPHAR

Guide to Pharmacology

UniProtKB

P18089

UniProt Accession

ADA2B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:281

GenAtlas

ADRA2A

GeneCards

ADRA2A

GenBank Gene Database

M23533

GenBank Protein Database

178196

IUPHAR

Guide to Pharmacology

UniProtKB

P08913

UniProt Accession

ADA2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10718

GenAtlas

SELE

GeneCards

SELE

GenBank Gene Database

M30640

GenBank Protein Database

182048

Guide to Pharmacology

3200

UniProtKB

P16581

UniProt Accession

LYAM2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4910

GenAtlas

HIF1A

GeneCards

HIF1A

GenBank Gene Database

U22431

UniProtKB

Q16665

UniProt Accession

HIF1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6265

GeneCards

KCNJ4

Guide to Pharmacology

432

UniProtKB

P48050

UniProt Accession

KCNJ4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6263

GeneCards

KCNJ2

UniProtKB

P63252

UniProt Accession

KCNJ2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2596

GenAtlas

CYP1A2

GeneCards

CYP1A2

GenBank Gene Database

Z00036

Guide to Pharmacology

1319

UniProtKB

P05177

UniProt Accession

CP1A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2595

GeneCards

CYP1A1

GenBank Gene Database

K03191

GenBank Protein Database

181276

Guide to Pharmacology

1318

UniProtKB

P04798

UniProt Accession

CP1A1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2631

GeneCards

CYP2E1

GenBank Gene Database

J02625

GenBank Protein Database

181360

Guide to Pharmacology

1330

UniProtKB

P05181

UniProt Accession

CP2E1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12530

GeneCards

UGT1A1

GenBank Gene Database

M57899

GenBank Protein Database

184473

Guide to Pharmacology

2990

UniProtKB

P22309

UniProt Accession

UD11_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12553

GeneCards

UGT2B4

GenBank Gene Database

Y00317

GenBank Protein Database

37589

UniProtKB

P06133

UniProt Accession

UD2B4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12554

GeneCards

UGT2B7

GenBank Gene Database

J05428

GenBank Protein Database

340080

UniProtKB

P16662

UniProt Accession

UD2B7_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2623

GenAtlas

CYP2C9

GeneCards

CYP2C9

GenBank Gene Database

AY341248

Guide to Pharmacology

1326

UniProtKB

P11712

UniProt Accession

CP2C9_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12805

GenAtlas

XDH

GeneCards

XDH

GenBank Gene Database

D11456

GenBank Protein Database

10336525

Guide to Pharmacology

2646

UniProtKB

P47989

UniProt Accession

XDH_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:399

GenAtlas

ALB

GeneCards

ALB

GenBank Gene Database

V00494

GenBank Protein Database

28590

UniProtKB

P02768

UniProt Accession

ALBU_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:40

GenAtlas

ABCB1

GeneCards

ABCB1

GenBank Gene Database

M14758

GenBank Protein Database

307180

Guide to Pharmacology

768

UniProtKB

P08183

UniProt Accession

MDR1_HUMAN

International reference pricing

35 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $0.79/tablet

To $4.77/capsule

Phl-Carvedilol 12.5 mg Tablet

$0.79/tablet

Phl-Carvedilol 3.125 mg Tablet

$0.79/tablet

Phl-Carvedilol 6.25 mg Tablet

$0.79/tablet

Pms-Carvedilol 12.5 mg Tablet

$0.79/tablet

Pms-Carvedilol 25 mg Tablet

$0.79/tablet

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

Patent information

All patents expired, 4 expired

8101209

United States

Paediatric ext.

Approved 24 Jan 2012 · Expires 11 Mar 2026

Expired

7268156

United States

Paediatric ext.

Approved 11 Sept 2007 · Expires 27 Dec 2023

Expired

6022562

United States

Paediatric ext.

Approved 8 Feb 2000 · Expires 17 Apr 2016

Expired

RE40000

United States

Paediatric ext.

Approved 8 Jan 2008 · Expires 7 Dec 2015

Expired

Patent protection has expired — generic versions may be available.

Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 27 days ago(8 Mar 2026)

Back to medicines

Carvedilol 3.125mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

NICE clinical guidance(1)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
31

Chemical identifiers

Carvedilol

Additional database identifiers

International reference pricing

Patent information

DrugBank citations

Carvedilol 3.125mg tablets

Pharmacogenomics alert

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(1)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science31

Chemical identifiers

Carvedilol

Additional database identifiers

International reference pricing

Patent information

DrugBank citations

Deep science
31